CIK 0001953926
- Emerging growth company
Zenas BioPharma, Inc.
Sign in to watch- Ticker
- ZBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 857-271-2954
- Business address
- 852 WINTER STREET, SUITE 250, WALTHAM, MA, 02451
- Former names
- Zenas BioPharma (Cayman) Ltd
- 4 Derivatives Options or other derivatives
- 4/A Open-market buy Director bought 10,000 shares at $7.76 ($77,600)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Chief Executive Officer bought 25,000 shares at $6.67 ($166,750)
- 4 Open-market buy Director bought 10,000 shares at $7.76 ($77,600)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Executive Officer bought 70,000 shares at an average $10.26 ($718,100)
- 4 Open-market buy Chief Executive Officer bought 10,000 shares at an average $14.89 ($148,925)
- 4 Open-market buy Chief Executive Officer bought 20,000 shares at an average $18.04 ($360,820)
- 4 Conversion 10% owner acquired 801,624 shares (conversion)
- 4 Open-market buy 10% owner bought 882,353 shares at $17.00 ($15,000,001)
- 4/A Open-market buy Director bought 300,000 shares at $17.00 ($5,100,000)
- 4/A Conversion Chief Executive Officer acquired 693,175 shares (conversion)
- 4 Open-market buy Director bought 58,823 shares at $17.00 ($999,991)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
Page 3 of 5 · 84 filings